Pharmacological intervention with XO inhibitors has shown that XO is involved in various acute-injury models, such as ischemia-reperfusion injury [22,23], hyperglycemic cardiomyopathy [24], and neurodegeneration induced by spinal cord injury [25]. This evidence concerns the gene XDH and ischemia reperfusion injury.